KOO vs. RENX, SCLP, FARN, DXRX, BVC, FUM, CEL, CREO, EKF, and EAH
Should you be buying Kooth stock or one of its competitors? The main competitors of Kooth include Renalytix (RENX), Scancell (SCLP), Faron Pharmaceuticals Oy (FARN), Diaceutics (DXRX), BATM Advanced Communications (BVC), Futura Medical (FUM), Celadon Pharmaceuticals (CEL), Creo Medical Group (CREO), EKF Diagnostics (EKF), and ECO Animal Health Group (EAH). These companies are all part of the "medical" sector.
Kooth (LON:KOO) and Renalytix (LON:RENX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, community ranking, risk, valuation and dividends.
Kooth has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, Renalytix has a beta of 1.92, suggesting that its stock price is 92% more volatile than the S&P 500.
79.6% of Kooth shares are held by institutional investors. Comparatively, 19.8% of Renalytix shares are held by institutional investors. 11.3% of Kooth shares are held by company insiders. Comparatively, 36.4% of Renalytix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Renalytix received 16 more outperform votes than Kooth when rated by MarketBeat users. However, 87.50% of users gave Kooth an outperform vote while only 74.19% of users gave Renalytix an outperform vote.
Kooth has higher revenue and earnings than Renalytix.
In the previous week, Kooth had 3 more articles in the media than Renalytix. MarketBeat recorded 4 mentions for Kooth and 1 mentions for Renalytix. Kooth's average media sentiment score of 0.60 beat Renalytix's score of 0.00 indicating that Kooth is being referred to more favorably in the media.
Kooth presently has a consensus target price of GBX 580, suggesting a potential upside of 122.22%. Given Kooth's higher probable upside, equities research analysts plainly believe Kooth is more favorable than Renalytix.
Renalytix has a net margin of 0.00% compared to Kooth's net margin of -0.51%. Kooth's return on equity of -1.08% beat Renalytix's return on equity.
Summary
Kooth beats Renalytix on 9 of the 15 factors compared between the two stocks.
Get Kooth News Delivered to You Automatically
Sign up to receive the latest news and ratings for KOO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KOO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
